3 "Strong Buy" Healthcare Stocks

Here are three "Strong Buy" healthcare stocks from Wall Street Here are three "Strong Buy" healthcare stocks from Wall Street                                                                                                      You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Dear Fellow Investor, In a world increasingly focused on health and well-being, the healthcare industry stands at the forefront of innovation and growth. The demand for quality healthcare services continues to surge, driven by an aging population, advancements in medical technology, and a global emphasis on preventative care. Investing in strong healthcare stocks presents a compelling opportunity, offering the possibility of robust returns and long-term stability. Here are three "Strong Buy" Healthcare stocks from Wall Street - Beam Therapeutics Inc. – SYM: BEAM Recent Price: $32.22 Price Target: $56.00 Firms with Buy Rating: Citi, Wells Fargo, Bank of America Securities Description: Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency.  === [[Free Event] How To Cash Flow Your Stocks]( Last year investors lost around $15 trillion. But had you known how to leverage the power of options safely… You could have turned your stock portfolio into cash… [Sign up here to join the live training event Wednesday at 7 PM EST!]( === Terns Pharmaceuticals, Inc. – SYM: TERN Recent Price: $8.11 [Get Price Target Here ]( Firms with Buy Rating: Goldman Sachs, Jefferies, BMO Capital Description: Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. === [Sick of Politics? This is a “must-see”]( [secret owner]( You can't avoid politics these days. Whether it's the debt ceiling… Fed rate hikes… or just the outrageous spending Washington has no interest in stopping. This new "must see" presentation, Financial Lockout with former hedge fund legend Whitney Tilson, may be the most important one you see this year. Whitney is a "one-percenter insider." [If you care at all about your financial future, I urge you to watch this presentation NOW.]( === Structure Therapeutics Inc. – SYM: GPCR Recent Price: $33.51 [Get Price Target Here ]( Firms with Buy Rating: Jefferies, BMO Capital, Guggenheim Description: Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California. === [Secret behind reclusive millionaire's 8-year win streak revealed]( See this revealing ‘tell all’ interview and discover the simple strategy that could turn every Friday into a payday. [Join right now!]( "The Buck Stops Here" [youtube button]( [facebook button]( [instagram button]( Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2023 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe](